Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.56 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404592 | 1.00 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL19243047 | 1.00 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL21546057 | 1.00 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL274179 | 0.89 | TDO2 (0.53) | CAPN1CAPN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL274178 | 0.89 | TDO2 (0.53) | CAPN1CAPN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL28707222 | 0.89 | TDO2 (0.53) | CAPN1CAPN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL12113193 | 0.84 | F7 (0.46) | KMT2AKDM4EALDH1A1GAAL3MBTL1 | |
| SCHEMBL11842039 | 0.84 | F7 (0.46) | KMT2AKDM4EALDH1A1GAAL3MBTL1 | |
| SCHEMBL11842043 | 0.84 | F7 (0.46) | KMT2AKDM4EALDH1A1GAAL3MBTL1 | |
| SCHEMBL31451476 | 0.82 | ALDH1A1 (0.60) | KMT2AMEN1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240327350-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11261157-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20190345103-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | CAPN1 1177/4885CAPN2 908/4885KMT2A 3151/4885 |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | CAPN1 1177/4885CAPN2 908/4885KMT2A 3151/4885 |
| US-20190345103-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | CAPN1 1177/4885CAPN2 908/4885KMT2A 3151/4885 |
| US-11261157-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | CAPN1 1177/4885CAPN2 908/4885KMT2A 3151/4885 |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | CAPN1 1177/4885CAPN2 908/4885KMT2A 3151/4885 |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | CAPN1 1177/4885CAPN2 908/4885KMT2A 3151/4885 |
| US-20240327350-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | CAPN1 1177/4885CAPN2 908/4885KMT2A 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.